Association of the Apolipoprotein B/Apolipoprotein A-I Ratio, Metabolic Syndrome Components, Total Cholesterol, and Low-Density Lipoprotein Cholesterol with Insulin Resistance in the Population of Georgia

Table 3

Descriptive characteristics between insulin resistant and insulin sensitive (men).

	Insulin sensitive	Insulin resistant	𝑃 value
Men 𝑛 (%)	659 (75.8)	210 (24.2)
Age	42.4±17.6	52±14.65	<.0001
ApoB/ApoA-I ratio	0.76±0.19	1.12±0.32	<.0001
ApoA-I (g/L)	1.05±0.42	1.04±0.30	<.0001
ApoB (g/L)	0.78±0.30	1.11±0.36	<.0001
SP (mmHg)	133±21.77	171±23.26	<.0001
DP (mmHg)	83.5±12.04	106±13.28	<.0001
WC (cm)	87.5±9.27	107.9±11.43	<.0001
BMI (kg/m^2)	25.5±5.19	36.58±5.39	<.0001
HDL-C (mmol/L)	1.25±0.19	0.99±0.19	<.0001
LDL-C (mmol/L)	2.81±0.57	3.85±0.63	<.0001
FG (mmol/L)	5.31±0.6	6.07±0.69	<.0001
FIns (𝜇U/mL)	10.82±4.99	29.58±7.96	<.0001
Tryg (mmol/L)	1.86±0.42	2.46±0.42	<.0001
TC (mmol/L)	4.63±0.64	5.64±0.65	<.0001
MetS 𝑛 (%)	163 (24.7)	199 (94.8)	<.0001
AH 𝑛 (%)	377 (57.2)	180 (85.7)	<.0001
Dyslipidemia 𝑛 (%)	313 (47.5)	205 (98)	<.0001

Data are expressed as mean ± SD.
The Mann-Whitney U test was used to compare the data between insulin sensitive and insulin resistant.
Chi-square test was used to compare the prevalence of MetS, AH, and dyslipidemia between insulin sensitive and insulin resistant.
ApoB/ApoA-I ratio: apolipoprotein B/apolipoprotein A-I ratio, ApoA-I: apolipoprotein A-I, ApoB: apolipoprotein B, SP: systolic blood pressure, DP: diastolic blood pressure, WC: waist circumference, BMI: body mass index, HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol, FG: fasting glucose, FIns: fasting insulin, TG: triglyceride, TC: total cholesterol, HOMA2-IR: homeostasis model assessment of insulin resistance, MetS: metabolic syndrome, and AH: arterial hypertension.
Insulin sensitive (defined as the gender-specific first three quartiles) HOMA2-IR (homeostasis model assessment of insulin resistance) <2.9; insulin resistant (defined as the gender-specific upper quartile) HOMA2-IR (homeostasis model assessment of insulin resistance) ≥2.9.